KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Other: 2021-2024

Historic Receivables - Other for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2024 value amounting to $49.2 million.

  • Recursion Pharmaceuticals' Receivables - Other rose 298.36% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year increase of 298.36%. This contributed to the annual value of $49.2 million for FY2024, which is 1489.08% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Receivables - Other of $49.2 million as of FY2024, which was up 1,489.08% from $3.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Receivables - Other ranged from a high of $49.2 million in FY2024 and a low of $2.8 million during FY2022.
  • In the last 3 years, Recursion Pharmaceuticals' Receivables - Other had a median value of $3.1 million in 2023 and averaged $18.3 million.
  • In the last 5 years, Recursion Pharmaceuticals' Receivables - Other slumped by 69.60% in 2022 and then soared by 1,489.08% in 2024.
  • Over the past 4 years, Recursion Pharmaceuticals' Receivables - Other (Yearly) stood at $9.1 million in 2021, then tumbled by 69.60% to $2.8 million in 2022, then grew by 12.39% to $3.1 million in 2023, then surged by 1,489.08% to $49.2 million in 2024.